

BIO-GENE TECHNOLOGY LIMITED

ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES

OCTOBER 2021

INVESTOR UPDATE

PRESENTED BY

Richard Jagger

Chief Executive Officer &
Managing Director

20
21

BIO-GENE
TECHNOLOGY
LTD



DISCLAIMER

This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an offer or invitation in respect of securities in the Company. No agreement to subscribe for securities will be entered into on the basis of this presentation or any information contained in this presentation.

This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of another jurisdiction. This presentation is provided for general information purposes only and is selective, does not purport to contain all relevant information and has not been independently verified.

Neither the Company nor its advisors have any responsibility or obligation to inform any recipient of any matter arising or coming to their notice after the date of this presentation, which may affect any matter referred to in the presentation. The Company releases material information as announcements to the ASX (ASX:BGT). Recipients seeking further information in respect of the Company should review the Company's announcements as released to ASX from time to time.

Nothing in this presentation constitutes investment, legal, tax, accounting or other advice. The recipient should consider its own financial situation, objectives and needs and conduct its own independent investigation and assessment, including obtaining investment, legal, tax, accounting or other advice as it considers necessary or appropriate.

The distribution of this presentation (including electronic copies) outside Australia may be restricted by law and persons who come into possession of this presentation outside Australia should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

This presentation may contain statements relating to intentions, future acts and events (Forward Looking Statements). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed. No representation, warranty or guarantee, express or implied, is given that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable.

No financial information (unless also contained in financial reports released to ASX), estimates or projections contained in this presentation or as derived from such financial information, estimates or projections can be relied upon as a promise or representation as to any present or future matter.

To the maximum extent permitted by law, neither the Company nor any of its associates, directors, officers, employees, advisors or representatives make any representation or provide any warranty, express or implied, as to the accuracy, reliability or completeness of the information contained in this presentation or any subsequent information provided to the recipient including, but not limited to, any financial projections, estimates or other historical information.

Significant positive progress across multiple fronts

BGT continues to execute on a strategy to secure commercial partnerships that help validate our technology and establish meaningful future value streams



Australian technology with the potential to make a global difference

New, natural and novel chemistry has the opportunity to address resistance issues impacting food security and public health

New agreements with commercial partners

- | | |
|-------------------------------|---|
| Development agreements | BGT has executed a commercial development agreement with Evergreen Garden Care and has negotiated an exclusive option with Clarke Mosquito Control |
| Additional MTAs | BGT has entered into new Material Transfer Agreements (MTAs) with large international companies focused across the various market segments where our technology has potential application |

Building our efficacy data

- | | |
|---------------------------|---|
| Recent results | Positive results from the Phase 2 studies undertaken with Clarke on mosquito control |
| Regulatory support | Completion of independent review by CRO to determine optimal pathway for US and European active ingredient registration |

Strengthening our IP

- | | |
|-----------------------------|---|
| New patent allowance | US Patent Office allows patent relating to management of pesticide resistant insects using Bio-Gene molecules |
| Additional IP | Programs underway to strengthen IP relating to manufacturing and extraction processes |
-

BIO-GENE ANNOUNCES COMMERCIAL DEAL WITH EVERGREEN GARDEN CARE



Evergreen is a market leader in consumer products across Europe and in Australia/New Zealand marketing major brands such as:



“We are excited to be partnering with Bio-Gene to develop natural consumer pest control products based on molecules with a new Mode of Action. The early work we have done suggests this natural technology could be the basis of truly differentiated and efficacious products that will be essential to meet the needs of consumers in our key markets. Our commitment to invest substantial R&D funds in the further development of these products is a reflection of our confidence in the market potential of the natural technology and our commitment to delivering innovation through partnerships”.

Global Innovation and Product Director for Evergreen, Ann-Marie O’Riordan

Affiliation with Scotts / Miracle Grow

Evergreen was formed through the acquisition of the European and Asia Pacific operations of Scotts Miracle-Gro, the world’s leading marketer of branded consumer products for home, lawn and garden care. Evergreen have licence agreements providing access to brands and product development

EVERGREEN COMMERCIAL DEVELOPMENT AGREEMENT

Initial Field of Use

Fly & mosquito electric evaporator
Ant bait gel and ant spray

ROFR to negotiate additional applications within consumer market

Market Size

Evaporator & Ant control market approximately US\$600 m¹

European consumer insecticide market US\$2 billion¹

Initial Territory

European Union, United Kingdom, Norway, Switzerland, Australia, New Zealand

ROFR to negotiate additional territories within consumer market

Evergreen Development Obligations

Development and registration of end-use products relating to agreed fields of use and territories

Evergreen will continue to evaluate and identify additional applications to bring to the table for negotiation. Bio-Gene will also look for opportunities via its internal on-going research

Incentive for both parties exists to continue to grow the relevant market applications

Market Segment

Consumer products

Term

Life of patents

Initial applications attract licence fees and milestones over next 3 years, with additional applications to be negotiated

Ongoing royalties on sales

NEW OPTION AGREEMENT SIGNED ON CLARKE MOSQUITO PROJECT

Results of Phase 2 Testing

Very positive results indicate the suitability of Bio-Gene products as mosquito control technology

Target formulations identified for progression to Phase 3 field trials

Confidence for both companies to move forward with commercial negotiations as per the Option agreement

New Option Agreement Signed

90 Days to complete full commercial terms

Exclusive period to begin Phase 3 field testing

Agreement is for the U.S. market

Cost of studies borne by Clarke, with shared report of results

Next Steps

Clarke to confirm timing for the field component of Phase 3 trials (somewhat weather dependent)

Field studies designed to confirm suitability of laboratory developed formulations for field use

Strong Negotiation Position for Bio-Gene

The Option Agreement allows for the best opportunity for Bio-gene to negotiate favourable terms going forward.



Data generated under Clarke MTA and Phase 2 testing suggests significant value of Bio-Gene technology in the mosquito control market

Supported by studies conducted at Purdue University

Other companies now performing internal testing specifically focused on mosquitos

UPDATE ON BASF STORED GRAIN PROJECT

Details of Current Agreement with BASF

Term of exclusivity to have option for stored grain market within Australia

Results of Phase 3 Testing

Field testing will be completed Nov/Dec 2021

Lab testing required to test stored grain efficacy F1 progeny

Report to then be generated

Final reporting on these results expected early in 2022

Next Stage

Involves commitment to the regulatory studies required for registration, including residual and toxicity work and label development

Further Discussions

Bio-Gene and BASF are discussing terms covering the commitment required of each party to progress the commercial development of Flavocide as a stored grain protectant

Studies to date show the ability for Flavocide, when used in combination, to control the full range of stored grain pests, over commercially viable time frames. Final stage of Phase 3 will show data across 9 months.

Earlier studies showed suitable efficacy for Flavocide on its own for 13 months.

MANUFACTURING & REGULATORY UPDATE

Flavocide

- Flavocide manufacturing validation – scale-up process has confirmed ability to produce larger quantities
- Multiple batches of Flavocide produced
- Batches being formulated for use in testing by commercial companies

Review Of Reg Requirements

- Completed a regulatory review analysis with global consultants to look at the specific data requirements for USA, European Union, Australia across our different market segments
- Clear understanding developed relating to read-across potential for different applications and regulatory jurisdictions.

Qcide

- Last harvest confirmed production improvements based on modified temperature and pressure
- 5 batch production completed for regulatory purposes

Benefits

- Creates confidence to proceed with next round of studies and their relevance to all of our leading market opportunities
- Coordinating regulatory activities with our commercial partners is critical for optimum timing of Active Ingredient and End Use Product registrations

Next Steps

- Finalisation of the Flavocide 5 batch production and analysis for the regulatory dossier
- At next harvest, expected Q1 2022, trial new harvester which produces small biomass size to allow for greater steam processing of leaf matter to capture more eucalyptus oil (Qcide)
- 5 batch analysis for Qcide regulatory dossier

On-going advancements in production of Flavocide and Qcide provide confidence to Bio-Gen and commercial partners.

The critical regulatory studies required for registration are compatible across most of our target market applications.

IMPORTANT PROGRESS ACROSS OTHER AREAS

Efficacy: Crop Pests

- Final stage of CRO testing underway
- Focus is on a range of key commercial species, targeting potential synergistic or additive effects
- Creates an additional data set for discussions with crop protection companies as well as new I.P.

Additional MTAs

- Bio-Gene has signed 4 new MTAs this calendar year with international companies focused across all areas of insecticide use
- Studies performed by these companies ultimately give Bio-Gene additional options for going to market

Efficacy: Non-crop Pests

- Additional studies underway for specific company evaluation of technology
 - Animal Health
 - Consumer
 - Public Health
- Extension work to identify additional key targets and applications to support our commercial discussions and further develop our I.P. portfolio

Patent Allowances

- 2 granted in Australia
- 1 recently granted in United States
- Under review in other key markets

I.P. Developments

- Additional research underway has the potential to identify new I.P. for the company
- I.P. can be in the form of patents, technical knowhow, trade secrets

On-going research is focused on developing data to support key commercial discussions as well as enhancing our I.P. portfolio

Bio-Gene continues to expand its market network and identify new data that further differentiates our I.P. position

FUNDING POSITION

Shares on issue
152, 619, 401

Market capitalisation
\$29.8 million¹

As at September 30, 2021,
Cash on hand
A\$3.2 million

Provides working capital
needs on budgeted
activities well beyond

June 2022

1. @19.5 cents per share

Sources of future funding:



Development
and commercial
partnerships



Industry
organisations



Government
grants



Capital markets



Philanthropic
organisations
focused on public
health solutions

KEY INVESTMENT HIGHLIGHTS

Proprietary insecticide technology

Naturally derived chemistry, with novel mode of action



Expanding efficacy, toxicity and manufacturing data to support international regulatory submissions – Excellent safety profile



Large addressable markets

where insecticide resistance is a growing problem



Commercial partnership strategy

provides multiple opportunities to demonstrate and generate near-term value, with several partnerships already in place



Experienced and motivated management team



BIO-GENE TECHNOLOGY LIMITED

ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES

CONTACT



RICHARD JAGGER
CHIEF EXECUTIVE OFFICER

richardj@bio-gene.com.au

BIO-GENE
TECHNOLOGY
LTD

